Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting.

NAR Cancer · 2025 · PMC12723232 · PMID 41446759

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A Phase II trial ( NCT00540722 ) added gossypol to cisplatin/docetaxel in NSCLC patients with high APE1 tumors, but it did not significantly improve outcomes (though there was a nonsignificant trend toward longer survival) [ 168 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.